Is MelanomaNext the right test for you?
Melanoma is a type of skin cancer that can spread to other organs in the body – it is commonly associated with exposure to sunshine or artificial tanning, but it can be hereditary. If you have had one or more primary melanoma – or maybe there is a history of melanoma or other cancers in your family, this test could be for you.
It involves analysis of an 8 gene panel designed to provide more precise data to guide you about risk prevention and screening programmes.
To get this test you will first need a consultation with your clinician, then you can either:
- Buy it directly from this website (this cost may be covered by your medical insurance).
- Access it through your treating hospital/private healthcare provider.
This test is only available to those aged 18 years or above.
- Why?►Close tab
Would more frequent screening help you?
This test can help your clinician decide at what age and how often you should have screening for melanoma and other cancers
Lifestyle choices which can reduce your risk
There are no sure ways of preventing melanoma, but if you know you are at risk, there are things you can do to help make it less likely that you will develop this and other skin cancers. Many of these are about reducing your exposure to the sun by wearing sunscreen, sun-protective clothing such as hats and sunglasses and seeking shade during the hours when the sun’s rays are most intense.
This test can also indicate if other member of your family may have hereditary risk of developing melanoma or other cancers – and therefore what steps they need to take for further screening or monitoring.
You can discuss this with your clinician, or if you would like to talk to one of our experts about the test, call us on +44 (0) 7495 981816
- How?►Close tab
What do I need to do?
It’s usually a simple ‘spit test’ – all we need is your saliva. You’ll receive a kit with clear instructions on giving your sample.
- Process►Close tab
Buying the test
Step 1: There are two options:
- Via your treating hospital/private healthcare provider (we have special arrangements with many healthcare providers to enable you to access this test, click here to see the list)
- By clicking the ‘Buy direct now’ button above (the cost may be covered by your medical insurance – check your policy details)
Step 2: Collection of sample
We will liaise directly with your clinician and organise the collection of your sample and delivery to the laboratory.
Step 3: Analysis and reporting
Your sample will be analysed and a report will be generated, usually within four to five weeks of receipt of your sample in the laboratory.
Step 4: Results
Your clinician will receive the test report giving a clear indication of whether you are at risk of melanoma or if you have already been diagnosed, what steps you – and possibly other members of your family – need to take next.
- Clinicians►Close tab
Is MelanomaNext the right test for your patient?
MelanomaNext is a next generation sequencing panel that simultaneously analyses 8 genes associated with increased risk for melanoma and other cancers.
When to consider testing
- Multiple primary melanomas
- Multiple close relatives* with melanoma, with or without pancreatic cancer
- Melanoma and kidney cancer (or mesothelioma) in the same person, or close relatives*
- A family history of a mutation in a gene that predisposes to melanoma
* On the same side of the family
Mutation Detection Rate
MelanomaNext can detect >99.9% of described mutations in the included genes listed above, when present (analytic sensitivity).
- Test Description
MelanomaNext analyses 8 genes (listed above). All genes are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for PTEN (c.-1300 to c.-745). The BRCA2 Portuguese founder mutation, c.156_157insAlu (also known as 384insAlu) is detected by NGS and confirmed by PCR and agarose gel electrophoresis. For MITF, only the status of the c.952G>A (p.E318K) alteration is analysed and reported.
Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.1
Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of all 7 genes (excluding MITF) using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray.
Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.
This test is provided by:
Frequently asked questions
- Do I need a doctor to authorise this test?
- Yes, your doctor will need to provide the sample required for this test
- Will my health insurance cover the cost of this test?
- Many health insurance plans cover the cost of genetic testing – check with your provider to find out if it is in your policy.
- How soon do I get my results?
- Usually within four to five weeks of receipt of your sample in the laboratory.
- How accurate is the test?
- Ambry follows advanced laboratory procedures and ensures quality control to deliver accurate results you can trust.